Tissue-specific autoimmunity occurs when selected antigens presented by susceptible alleles of the major histocompatibility complex are recognized by T cells. However, the reason why certain specific self-antigens dominate the response and are indispensable for triggering autoreactivity is unclear. Spontaneous presentation of insulin is essential for initiating autoimmune type 1 diabetes in non-obese diabetic mice 1,2 . A major set of pathogenic CD4 T cells specifically recognizes the 12-20 segment of the insulin B-chain (B:12-20), an epitope that is generated from direct presentation of insulin peptides by antigen-presenting cells 3,4 . These T cells do not respond to antigen-presenting cells that have taken up insulin that, after processing, leads to presentation of a different segment representing a one-residue shift, B:13-21 4 . CD4 T cells that recognize B:12-20 escape negative selection in the thymus and cause diabetes, whereas those that recognize B:13-21 have only a minor role in autoimmunity 3-5 . Although presentation of B:12-20 is evident in the islets 3,6 , insulin-specific germinal centres can be formed in various lymphoid tissues, suggesting that insulin presentation is widespread 7,8 . Here we use live imaging to document the distribution of insulin recognition by CD4 T cells throughout various lymph nodes. Furthermore, we identify catabolized insulin peptide fragments containing defined pathogenic epitopes in β-cell granules from mice and humans. Upon glucose challenge, these fragments are released into the circulation and are recognized by CD4 T cells, leading to an activation state that results in transcriptional reprogramming and enhanced diabetogenicity. Therefore, a tissue such as pancreatic islets, by releasing catabolized products, imposes a constant threat to self-tolerance. These findings reveal a self-recognition pathway underlying a primary autoantigen and provide a foundation for assessing antigenic targets that precipitate pathogenic outcomes by systemically sensitizing lymphoid tissues.
T cells ( Fig. 1d , Supplementary Video 2). Motility was reduced to a similar degree on day 1 or day 5 of imaging (Extended Data Fig. 1c ), and was unaffected by switching the labelling of the fluorescent probes (Extended Data Fig. 1d ). The diffuse, rather than clustered, pattern of motility arrest indicates that presentation of insulin peptides was limiting and was not restricted to selected antigen-presenting cells (APCs). Motility of 8F10 T cells was also reduced in µMT and Batf3 -/mice, which are deficient in B cells and XCR1 + dendritic cells, respectively (Extended Data Fig. 1e ).
We performed three experiments to interrogate key parameters of antigen recognition by 8F10 T cells. First, we examined B16A mice, which are deficient in both Ins1 and Ins2 but express a proinsulin transgene with a Tyr16Ala substitution in the B chain 1 . This mutant insulin is bioactive but is not immunogenic to B:12-20-or B:13-21specific T cells. There was no reduction in motility of 8F10 T cells in the B16A mouse recipients, demonstrating that the effects on T cell motility require specific epitope recognition by the 8F10 T cells ( Fig. 1e , Supplementary Video 3). Second, we investigated whether prior recirculation through the pLN was required for insulin recognition in other sites. Surgical removal of pLNs did not influence the motility arrest of 8F10 T cells in the iLNs (Fig. 1f ). Third, we detected motility arrest of 8F10 T cells in diabetes-resistant B6 mice harbouring the I-A g7 haplotype (B6g7) ( Fig. 1g ) but not in NOD mice with the H2b haplotype (Extended Data Fig. 1f ). Therefore, peripheral insulin presentation to 8F10 T cells requires I-A g7 and is not restricted to the NOD strain.
The motility of 4F7 T cells, which specifically recognize the B:13-21 epitope, was also markedly reduced in the pLNs and iLNs of NOD recipients (Extended Data Fig. 1g ). By contrast, the 8.3 CD8 T cells, which recognize the islet-specific glucose-6-phosphatase-related protein (IGRP 13 , a protein that is expressed in the endoplasmic reticulum of β-cells), exhibited reduced motility in the pLN but not in the iLN (Extended Data Fig. 1h ). Therefore, epitopes of insulin, but not those from IGRP, a cell-associated antigen, are systemically available.
We hypothesized that presentation of the low concentrations of circulating insulin (about 40 pM) might require insulin receptor-mediated uptake by APCs. To test this, we examined the effects of S961, an insulin receptor antagonist 14 . In assays on cultured cells, S961 impaired the ability of concanavalin A (ConA)-activated macrophages to present insulin (Extended Data Fig. 1i ). In vivo blockade of insulin receptor by infusion of mice with S961 via osmotic pump caused a sustained increase in blood glucose levels (Extended Data Fig. 1j ), permitting two-photon microscopy analysis (Extended Data Fig. 1k ). A significant reduction in mean velocity of transferred 4F7 T cells was observed in lymph nodes of control mice infused with phosphate-buffered saline (PBS) ( Fig. 1h, Supplementary Video 4) . Although the motility of 4F7 T cells was also arrested after S961 infusion, the magnitude of the reduction was significantly smaller than with PBS ( Fig. 1h, Supplementary  Video 4) . Therefore, blockade of insulin receptor-mediated uptake of insulin partially abrogated recognition by the 4F7 T cells, suggesting that free insulin peptides are an additional source of the B: [13] [14] [15] [16] [17] [18] [19] [20] [21] Letter reSeArCH epitope. By contrast, the motility arrest of 8F10 T cells remained at a comparable level in recipients infused with PBS or S961 ( Fig. 1i , Supplementary Video 5), indicating that the presence of B:12-20 is independent of insulin receptor-mediated uptake of insulin. This epitope must therefore derive from insulin peptides that reach the peripheral lymphoid organs. Of note, APCs expressing autoimmune Letter reSeArCH regulator (AIRE) 15 are not a major source of insulin peptides (Extended Data Fig. 1l ). We identified insulin peptides in β-cell granules using peptidespecific monoclonal antibodies and mass spectrometry analysis. We used the monoclonal antibody AIP, which is specific for B:9-23 3,6 , and generated a new monoclonal antibody (clone 6F3.B8) by immunization with the entire insulin B-chain (B:1-30). The two antibodies were not cross-reactive and neither recognized native insulin (Extended Data Fig. 2a-d) . Notably, presentation of B:1-30 activated insulinreactive T cells without the need for internal processing (Extended Data Fig. 2e ).
We previously identified B:9-23 in a set of LAMP1-positive vesicles in β-cells 3 . These vesicles are distinct from insulin-containing dense core granules and can be separated from them by differential centrifugation 6 . They are consistent with the crinophagic bodies that result from fusion of the dense core granules to lysosomes [16] [17] [18] , and contain peptides that preferentially stimulate 8F10 T cells 6 .
Immunofluorescence with AIP showed a punctate pattern of B:9-23 staining in β-cells from NOD.Rag1 −/− or B6g7.Rag1 −/− mice ( Fig. 2a ). By contrast, B:1-30 staining using 6F3.B8 was more diffuse in nearly all the β-cells and co-stained with insulin ( Fig. 2b ). Using double immunogold-labelling antibodies, we detected B:1-30 in granules containing insulin ( Fig. 2c ). Many granules (106 out of 317, 33%) contained both B:1-30 and insulin (Fig. 2d ), and the rest contained only insulin ( Fig. 2e ). AIP did not stain islets satisfactorily after labelling with immunogold.
Regular secretory granules obtained by centrifugation at 25,000g (25k) contained significantly higher amounts of insulin than the fraction obtained at 5,000g (5k), which includes the crinophagic bodies ( Fig. 2f) . B:1-30 was primarily found in the 25k fraction and not in the 5k fraction, but in concentrations about one tenth that of insulin ( Fig. 2f ). By contrast, B:9-23 was significantly more abundant in the granules in the 5k fraction ( Fig. 2f ).
We analysed the peptidomes of granules prepared from B6g7 mice, B6 mice or 3-week old female NOD mice, by nanoflow liquid chromatography-tandem mass spectrometry (nLC-MS/MS). In all three strains, granules from the 25k fraction mostly contained sequences from the insulin C-peptide, the intact B:1-30, and a few small peptides from the B chain ( Fig. 2g , h, Supplementary Table 1 , Extended Data Fig. 3a ). By contrast, the granules from the 5k fraction, contained more diverse short sequences from throughout the B chain ( Fig. 2g , h, Supplementary Table 1 ). Peptides derived from the 9-23 region, such as B:9-23 and B:11-23 (Extended Data Fig. 3b ), were identified exclusively in the 5k granules of all three mouse strains. Manual interrogation of unassigned spectra only identified two putative hybrid peptides in the 5k granules (Extended Data Fig. 3c ), a C-peptide-islet amyloid polypeptide (IAPP) fusion, and a fusion of the N terminus of the C-peptide of insulin-2 and the C terminus of the C-peptide of insulin-1. Peptides from other proteins were present at much lower levels in comparison to those from insulin.
Examination of β-cell granules from human islets revealed a striking similarity in the segregation of peptides between 5k and 25k fractions to that from the mouse islets (Extended Data Fig. 4a , Supplementary  Table 1 ). The human 25k granules contained the intact B chain and a limited number of short sequences. The 5k fraction contained many short peptides, including a sequence representing B:11-30 (Extended Data Fig. 4b ), containing the HLA(DQ8)-binding B:11-23 determinant, which is recognized by peripheral T cells in patients with type 1 diabetes 19 .
Islets stimulated with 25 mM glucose secreted insulin ( Fig. 3a ) along with lower concentrations of peptides that were recognized by 6F3.B8 ( Fig. 3b ) or AIP ( Fig. 3c ). Secretion of insulin or insulin peptides was not affected when glucose challenge was carried out in the presence of protease inhibitors (Extended Data Fig. 5a ), indicating that the peptides were not generated extracellularly.
We characterized insulin peptides secreted by β-cells using nLC-MS/MS. Most of these peptides were derived from the C-peptide, along with B-chain-derived sequences related to the 9-23 region and spanning the B-chain-C-peptide (B-C) junction ( Fig. 3d , Supplementary  Table 2 ). Many of the peptides were identical to or contained pathogenic epitopes that were identified using diabetogenic T cells as probes 1,3,4,20-22 ( Fig. 3e , Extended Data Fig. 5b-e ). The intact B chain contained identical sequences to peptides identified in the 25k granules, whereas B:9-23 and B:11-23 were identical to peptides in the 5k granules ( Fig. 3e , Supplementary Table 2 ). Synthetic versions of peptides associated with B:9-23 activated T cells specific for B:12-20 as well as those specific for B:13-21 (Extended Data Fig. 6 ). In general, these potentially immunogenic peptides were present at low relative abundance ( Fig. 3f , Supplementary Table 2) .
We identified a form of B:9-23 containing cysteine oxidized to cysteic acid in mouse urine using antibody capture ( Fig. 3g ); this is a modification that can occur during sample preparation (Extended Data Fig. 7a ). This finding indicates that B:9-23 is present in the circulation. Indeed, fluorochrome-labelled B:9-23 was rapidly displayed 
Insulin-1,2 SLYQLENYCN A:14-20 Insulin-1,2 YQLENYC A:14-21 In B-C-spanning peptides, the residues of the B chain are shown in bold. f, Box plot of log 2 (peak area) showing abundance of individual B:9-23associated peptides (blue), B-C-spanning peptides (red) and the A:14-20 peptide (cyan) relative to all insulin peptides (box). Box plots show the median, box edges represent the first and third quartiles, and the whiskers extend to 1.5× interquartile range. g, The mass spectrum of a peptide sequence identified in mouse urine that contains all residues of the insulin B:9-23 peptide, with oxidation of cysteine to cysteic acid (c).
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by I-A g7 -expressing APCs in spleen but not in thymus following intravenous injection (Extended Data Fig. 7b , c).
The widespread presentation of insulin peptides in lymphoid tissues influences the biology of T cells. We generated a bone marrow chimaera model in which we transferred a small number of bone marrow stem cells from CD45.2 8F10 mice deficient in T-cell receptor alpha chain (8F10 TCRα-/-) into non-lethally irradiated NOD or B16A hosts (CD45.1) ( Fig. 4a ). This resulted in the development of a small number of 8F10 T cells (0.5-2%) among the endogenous CD4 T-cell repertoire (Extended Data Fig. 8a ). We performed RNA sequencing analysis (RNA-seq) on isolated 8F10 T cells from iLNs of both hosts ( Fig. 4a ).
Hierarchical clustering using Pearson's correlation revealed differences between the transcriptomes of 8F10 T cells sourced from NOD (8F10-NOD) and B16A (8F10-B16A) hosts ( Fig. 4b ). Gene-set enrichment analysis (GSEA) showed significant correlations between transcripts that were upregulated in the 8F10-NOD T cells with biological pathways involving oxidative phosphorylation (OXPHOS), Myc targets, fatty acid metabolism, mTOR complex 1 (mTORC1) signalling and DNA repair (Extended Data Fig. 8b ). The four most highly ranked gene sets ( Fig. 4c ) were associated with metabolic pathways, and involved transcripts encoding key kinases, intermediates and transcription factors (Extended Data Fig. 8c ) that have been shown to support T cell proliferation and functions 23 .
This metabolic reprogramming in 8F10 T cells from NOD mice was associated with an effector-like phenotype (Fig. 4d ). The gene sets that were upregulated in these cells are also highly expressed in CD4 T cells upon stimulation 24 , in CD8 T cells at the peak of expansion in comparison to the contraction phase 25 , and in CD8 effectors in comparison to exhausted T cells 26 . There is little overlap among these three sets of transcripts (Extended Data Fig. 9a, Fig. 4e ). According to GSEA, neither T cell set correlated with anergic CD4 27 or tolerant CD8 T cells 28 (Extended Data Fig. 9b ).
Functional analysis at the six-week time point revealed a higher capacity of effector cytokine (TNF and IFNγ) production (Extended Data Fig. 10a ) and cell proliferation (Extended Data Fig. 10b ) in 8F10-NOD T cells. Neither T cell set expressed molecules associated with anergy and exhaustion 26, 27, 29 (Extended Data Fig. 10c ). Similar results were obtained for T cells analysed nine weeks after the bone marrow transfer (Extended Data Fig. 10d-f ). Of note, when the two sets of T cells were transferred into NOD.Rag1 −/− recipients, the onset of diabetes was accelerated by the 8F10-NOD set ( Fig. 4f ). Therefore, 8F10 T cells acquired an effector-like phenotype during peripheral antigen recognition, supported by transcriptional reprogramming and increased diabetogenicity.
In summary, peptide exocytosis is a normal response of β-cells that represents a mechanism of communication with the lymphoid tissues. Similar mechanisms may apply to other endocrine organs that also contain crinophagic granules. Examining the released peptides may enable better-targeted identification of T cell responses; a set of responses that could be extensive, given the diversity of exocytosed moieties. Previous studies have shown that ablation of all lymph nodes eradicates the pathogenic T cell repertoire and abolishes diabetes 30 , emphasizing the importance of the entire lymphatic system in interactions with T cells. Finally, the biological outcomes described here for 8F10 T cells may vary for other insulin-reactive T cells with divergent TCR affinities. Comprehensive understanding of these outcomes will require analysis of the entire insulin-reactive T cell pool at different stages of the disease.
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.2), NOD.B10Sn-H2b/J (NOD.H2b) and B6.NOD-(D17Mit21-D17Mit10)/LtJ (B6g7) mice were originally obtained from the Jackson Laboratory. NOD.10E11 TCR transgenic mice (TCRα: TRAV5D-4/ TRAJ42; TCRβ: TRBV13-3/ TRBD2/TRBJ2-7) were generated using a previous protocol 5 . NOD.4F7 TCR transgenic mice, NOD.Aire −/− , and NOD.TCRα −/− mice were generated by M.S.A. The 8F10 or 10E11 mice expressing the CD45.2 allotype were generated by intercrossing the original TCR transgenic line (CD45.1) with the NOD. CD45.2 mice, and the CD45.2.NOD.8F10 mice were further crossed with the NOD. TCRα −/− mice to generate the CD45.2 8F10 TCRα−/− mice. B6.Rag1 −/− mice were used to intercross with B6g7 mice to generate B6g7.Rag1 −/− mice. All mice were bred and maintained under specific pathogen-free conditions in our animal facility. All experiments were approved by the Division of Comparative Medicine of Washington University School of Medicine in St. Louis (Accreditation number A3381-01). Human pancreatic islets. De-identified human primary islets isolated from deceased donors were obtained from Prodo Laboratories. Experiments were judged to be 'not human subject research' by Washington University Human Research Protection Office (IRB ID # 201801183; Federalwide Assurance #FWA00002284). In total, islets from three donors were used: donor 1 (female, 57 years, BMI 21.35), donor 2 (female, 49 years, BMI 33), donor 3 (male, 28 years, BMI 34.7). Purity of the islets was between 85 and 98%. Islets were cultured in CMRL medium supplemented with 10% FBS and 50% L-cell conditioned medium 31 for recovery. The granules were isolated from ~1500 islets after 1-3 days of culture. Antibodies. The following fluorescently conjugated antibodies were purchased from BioLegend: anti-B220 (RA3-6B2), anti-CD11c (N418), anti-CD4 (RM4-5), anti-CD45 (30-F11), anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD8a (53-6.7), anti-F4/80 (BM8), anti-Vβ8.1/8.2 (KJ16-133.18), anti-CD44 (IM7), anti-CD62L (MEL-14), anti-CD25 (PC61.5) and anti-TNFα (MP6-XT22). Unconjugated or Alexa Fluor 647-labelled Rabbit anti-insulin monoclonal antibody(C27C9) was purchased from Cell Signaling Technology. Unconjugated mouse anti-insulin monoclonal antibody (E11D7) was purchased from Millipore. Alexa Fluor 594 F(ab) 2 donkey anti-mouse IgG and HRP-conjugated goat anti-mouse IgG (Fcγ-specific) were purchased from Jackson ImmunoResearch. Flow cytometry and cell sorting. Flow cytometry analysis was done as previously described 7 . The samples were examined using a FACSCanto II (BD Biosciences) and the data were analysed using FlowJo software (Tree Star Software). CD4 + T cells from iLNs were enriched using the CD4 + T cell isolation kit (Miltenyi Biotech), the 8F10 T cells were sorted as CD45.2 + CD45.1 − CD4 + CD8 − B220 − CD 11c − using FACSAria II (BD Biosciences). CFSE and CMTMR labelling. For two-photon imaging, naive CD4 T cells were purified by two rounds of MACS negative selection using the naive CD4 + T cell isolation kit (Miltenyi Biotech) to remove non-CD4 and CD44 + T cells. The CD25 + cells were further removed from the flow-through portion using the CD25 microbead kit (Miltenyi Biotech). The naive 8.3 or wild-type CD8 T cells were purified similarly by using the naive CD8 + T cell isolation kit. Flow cytometry analysis confirmed that >95% of the cells were CD4 + /CD8 + CD25 − CD62L hi CD44 − . CFSE (carboxyfluorescein succinimidyl ester) or 5-(and-6)-(((4-chloromethyl) benzoyl)amino)tetramethylrhodamine (CMTMR) labelling was performed using the Vybrant CFDA s.e. Cell Tracer Kit and the CellTracker Orange CMTMR Dye (both from ThermoFisher Scientific), respectively. In brief, T cells (10 7 /ml in PBS) were incubated with 10 µM CFSE or 8 µM CMTMR for 25 min at 37 °C with a gentle shake after 10 min. Under these conditions, T cells were labelled with satisfactory intensities without significant cell death. Ice-cold PBS was then added to quench the labelling. Adoptive transfer. CFSE-or CMTMR-labelled T cells were mixed 1:1 and were injected intravenously. For all the two-photon experiments, 2 × 10 6 T cells with either label were transferred. Varying T cell numbers in preliminary experiments determined that this amount resulted in a stable 0.5-0.8% reconstitution of the transferred T cells in the endogenous CD4 T cell pool, which was sufficient for two-photon imaging without causing obvious intraclonal competition. All the recipient mice were 3-4-week-old female mice unless otherwise mentioned. For experiments in Fig. 4f , FACS-sorted 8F10 T cells from pooled iLNs of 8-10 NOD or B16A mice were adoptively transferred intravenously into 4-6-week old NOD. Rag1 −/− recipients (10 5 cells per mouse). Two-photon imaging. Lymph nodes were removed, attached to coverslips, placed in CO 2 -independent medium (Gibco) at room temperature and immediately imaged in a perfusion chamber to simulate blood flow (36.5 °C DMEM; 95% O 2 and 5% CO 2 ). Two-photon microscopy images were collected using a customized Leica SP8 Two-Photon Microscope (Leica Microsystems) equipped with a 25× and 0.95 numerical aperture water-immersion objective and a Mai Tai HP DeepSee Laser (Spectra-Physics) tuned to 840 nm. Fluorescence emission was guided directly to external hybrid photodetectors (Leica/Hamamatsu). For signal separation, we used three separate dichroic beam splitters without bandpass filters (Semrock): 484-nm edge BrightLine (FF484-FDi01), 495-nm edge BrightLine (FF495-Di03), and 560-nm edge BrightLine (FF560-Di01). The mirrors were arranged in dendritic fashion. Stacks were collected with 2.5 µm between images with 25-30 images per stack.
For cell tracking, two or three regions of one lymph node were randomly selected and cropped. Cells were tracked manually in 3D volume using Imaris 8.41 software (Bitplane). We tracked the first 11 time points from each track (representing 5 min and 10 velocities between the time points). Each dot represents the mean velocity out of the 10 that were tracked. We also calculated the meandering index and the motility coefficient for each track. Note that we chose tracks with the same length since the track length impacts these last two parameters. The meandering index and the motility coefficient data are not shown for space reasons however the results support the velocity data. The mean track velocities (µm/min) were calculated for individual tracks as previously described 11 . Surgical removal of pancreatic lymph nodes. NOD mice (3-week old) were anesthetized with a 4% mixture of isoflurane in oxygen. The two pLNs were exposed by gently retracting the spleen, pancreas, stomach and intestines, and were grasped with blunt forceps. Using an ophthalmic cautery on low power, the blood vessels on either side of the pLNs were cauterized and the pLNs were removed. The sham surgery was performed with the same procedures except that the pLNs were exposed without removal. S961 administration. The S961 peptide (GSLDESFYDWFERQLGGGSGGSSLEEE WAQIQCEVWGRGCPSY) was synthesized by LifeTein, with an intrachain disulphide bridge between Cys33 and Cys40 (underlined). S961 (20 nMol/week) or control PBS was filled into the Alzet osmotic pump (2001 model, Durect) and inserted subcutaneously in the back of anaesthetized mice through an incision between scapula. Blood glucose levels were monitored twice a day (Chemstrip 2GP; Roche); mice with a level above 250 mg/dl for two consecutive measurements were considered diabetic. Competitive ELISA assay. 96-well ELISA plates were coated with human insulin solution (1 µg/well) or peptides B:1-30 or B:9-23 (2 µM), and were blocked with 3% BSA overnight at 4 °C. Soluble competitive inhibitors, including different synthetic peptides and biological samples, were pre-incubated with the E11D7 (100 ng/ml), 6F3.B8 (20 ng/ml), or AIP (4 ng/ml) monoclonal antibodies for 30 min and the mixture was added to the plate-bound antigens for 1 h at room temperature. In the absence of soluble competitive inhibitors, these concentrations of the monoclonal antibodies resulted in about a 50% binding to the plate-bound antigens. HRP-conjugated goat anti-mouse IgG (1:10000) antibody was then added for 1 h; the responses were developed using the OptEIA TMB Substrate (BD). The data (A 450 nm ) were collected using an iMark Microplate Reader (Bio-Rad Laboratories). For quantifying the biological samples, each experiment was paired with a standard curve in which serially diluted amounts of soluble antigens were used to suppress the binding of their cognate monoclonal antibodies to the same antigen in the plate-bound form. The degree of inhibition by the biological samples was calculated relative to the blocking curve used by the specific antigen using an equation generated by linear regression of the standard curve. Immunofluorescence microscopy. Mouse islets were isolated as previously described 7 . The islets were blocked with normal goat serum, fixed with 4% methanolfree formaldehyde, permeabilized with 0.2% saponin (Sigma), and stained with AIP or 6F3.B8 (50 µg/ml) for 45 min on ice. The samples were then stained with Alexa Fluor 594 F(ab) 2 donkey anti-mouse IgG (30 µg/ml), Alexa Fluor 647 Rabbit antiinsulin (20 µg/ml), and Alexa Fluor 488 anti-mouse CD11c (40 µg/ml) for 45 min on ice and mounted using the Prolong Diamond mountant (ThermoFisher). The samples were viewed using the Eclipse E800 microscope (Nikon) equipped with the EXi Blue fluorescence camera (Qimaging). Electron microscopy with Immunogold. Islets were fixed in 4% paraformaldehyde (Polysciences) in 100 mM PIPES, 0.5 mM MgCl 2 , pH 7.2 for 1 h at 4 °C. Samples were embedded in 10% gelatin and infiltrated overnight with 2.3 M sucrose/20% polyvinyl pyrrolidone in PIPES/MgCl 2 at 4 °C. Ultrathin sections of 50 nm were incubated with a blocking solution supplemented with 5% FBS and 5% normal goat serum for 30 min and subsequently incubated with rabbit anti-insulin (C27C9) and mouse anti-B chain (6F3.B8) antibodies for 1 h at room temperature. Sections were subsequently incubated with goat anti-mouse IgG conjugated to 18 nm colloidal gold and goat anti-rabbit IgG antibody conjugated to 12 nm colloidal gold for 1 h. Sections were stained with uranyl acetate and lead citrate and viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA) equipped with an AMT 8megapixel digital camera and AMT Image Capture Engine v.602 software (Advanced Microscopy Techniques). All labelling experiments were conducted in parallel with controls omitting the primary antibody. These controls were consistently negative. Insulin secretion assay. Islets were equilibrated in DMEM supplemented with 10% FBS and 5.5 mM glucose for 24 h in 24-well plates. The medium was then replaced with 300 µl pre-warmed Krebs-Ringer-HEPES balance solution containing 0.2% BSA with 2.5 mM or 25 mM glucose. After 1 h incubation, the culture supernatants were collected for the competitive ELISA assay or mass spectrometry analysis. β-cell granule isolation. Mouse and human islets were dispersed using nonenzymatic dispersion solution (Sigma). Cells were resuspended in PBS and lysed by passing them through a cell homogenizer (Isobiotec). The lysate was centrifuged twice for 10 min at 500g, 4 °C to pellet cell debris. The supernatant was centrifuged for 10 min at 5,000g, 4 °C. The 5,000g spin was repeated on the supernatant and the two pellets were combined. This fraction was highly enriched in peptide-containing vesicles compatible with the crinophagic bodies, and as such have been labelled. This fraction may also contain organelles other than the insulin-containing ones. The supernatant after the 5,000g spin was centrifuged for 30 min at 25,000g, 4 °C to pellet secretory granules. This supernatant was discarded, and the 25000g pellet was suspended in 100 µl PBS. The microcentrifuge used for granule isolation was an Eppendorf 5417R (Eppendorf) with a FA45-24-11 fixed angle rotor. Fractions were frozen at −80 °C and thawed at 37 °C for five cycles to release the contents of granules. After freeze-thaw, complete protease inhibitor cocktail was added to the sample which was then concentrated by SpeedVac to <100µl. The sample was passed through C18 Ziptips (Pierce) and peptides then were eluted in 0.1% formic acid/95% acetonitrile and then dried with a SpeedVac. Sample preparation for mass spectrometry analysis. Biological samples were treated with 2.5% trifluoroacetic acid (TFA) to a final concentration of 0.36% (v/v), and the peptides were purified using the C18 Ziptips, eluted with 0.1% formic acid in 95% acetonitrile, and lyophilized. For peptide capture, TFA-adjusted mouse urine (12 ml) was cleaned up using C18 Sep Pak cartridges (Waters). The analytes retained by the cartridge sorbent were eluted with methanol, lyophilized, and reconstituted with 2 ml sterile PBS. The material was then incubated with a 1:1 mixture of sepharose pre-conjugated with AIP or 6F3.B8 monoclonal antibodies (1 ml slurry total) for 72 h at 4 °C with gentle rotation. The urine-sepharose mixture was poured into a Bio-Rad Econo column, and after extensive washing, the antibody-bound material was eluted with 10% acetic acid and lyophilized. Mass spectrometry. A Dionex UltiMate 1000 system (Thermo Scientific) was coupled to an Orbitrap Fusion Lumos (Thermo Scientific) through an EASY-Spray ion source (Thermo Scientific). Peptide samples were loaded (30 µl/min, 1 min) onto a trap column (100 µm × 2 cm, 5 µm Acclaim PepMap 100 C18, 50 °C), eluted (300 µl/min) onto an EASY-Spray PepMap RSLC C18 column (2 µm, 25 cm × 75 µm ID, 50 °C, Thermo Scientific) and separated with the following gradient, all % Buffer B (0.1% formic acid in ACN): 0-40 min, 2-22%; 40-50 min, 22-35%; 50-60 min, 35-95%; 60-70 min, isocratic at 95%; 70-71 min, 95-2%, 71-85 min, isocratic at 2%. Spray voltage was 1900 V, ion transfer tube temperature was 275 °C, and RF lens was 30%. Mass spectrometry scans were acquired in profile mode and MS/MS scans in centroid mode, for ions with charge states 2-7, with a cycle time of 3 s. For HCD, mass spectra were recorded from 375-1500 Da at 120K resolution (at m/z = 200), and MS/MS was triggered above a threshold of 2.5 × 10 4 , with quadrupole isolation (1.6 Da) at 30K resolution, and collision energy of 30%. Dynamic exclusion was used (35 s). For high SA EThcD, mass spectra were acquired from 350-1500 Da at 60K resolution, and MS/MS spectra were triggered for ions above a threshold of 5 × 10 4 with quadrupole isolation (0.7 Da) at 15K resolution. Fragmentation employed calibrated charge-dependent ETD, with SA (40%) applied in the HCD cell. Dynamic exclusion was used (60 s). For low SA EThcD, mass spectra were recorded from 375-1500 Da at 120K resolution (at m/z = 200), and MS/MS spectra were acquired for ions above a minimum intensity threshold of 2.5 × 10 4 at 15K resolution. ETD reaction time was fixed at 100 ms, with SA (15%) applied in the HCD collision cell. Mass spectrometry data analysis. Data files were uploaded to PEAKS 8.0 (Bioinformatics Solutions) for processing, de novo sequencing and database searching. Resulting sequences were searched against the UniProt Mouse Proteome database (downloaded 8 June 2017; 25,144 entries) with mass error tolerances of 20 ppm and 0.02 Da for parent and fragment, respectively, no enzyme specificity and no fixed or variable modifications. The Common Repository for Adventitious Proteins database (www.thegpm.org/crap/) was used to identify contaminant proteins. FDR estimation was enabled. Peptides were filtered for −10log P ≥ 20, and proteins were filtered for −10log P ≥ 30 and one unique peptide. For all experiments, this gave an FDR of <1% at the peptide-spectrum match level. Peptides matching to insulin-1 and insulin-2 were manually verified by visual inspection. For relative quantification, peak areas for all manually verified peptides were exported from PEAKS, normalized to the total ion current, and log 2 transformed. T cell stimulation and antigen presentation assay. In Extended Data Fig. 1i , ConA-stimulated peritoneal macrophages were treated with 0.2 or 1 µM S961 for 1 h at 37 °C and were then cultured with the IIT-3 T cell hybridoma that recognizes the 13-21 peptide, in the presence of serially diluted insulin (I9278; Sigma). In Extended Data Fig. 2e , C3g7 cells were treated with chloroquine for 2 h at 37 °C, washed, pulsed with the antigens, and cultured with T cell hybridomas. After incubation for 18 h, the culture supernatants were assayed for IL-2 production. Bone marrow chimaera. The female donor 8F10.TCRα -/-(CD45.2) mice were injected intraperitoneally with fluorouracil (200 mg/kg), and bone marrow cells were isolated from the femur and tibia on day 5. The cells were adoptively transferred into sublethally irradiated (600 rads) 3-week old female NOD or B16A hosts (10 4 /mouse). RNA-seq analysis. Total RNA was isolated using the Ambion RNAqueous-Micro kit (Thermo Fisher Scientific). RNA-seq library preparation and sequencing was performed as previously described 32 . The differential expression analysis was done with the DESeq2 package (version 1.18.1). Multifactor analysis was used to account for donor effect. Specifically, paired 8F10-NOD and 8F10-B16A samples from one isolation (four pairs in total) were treated as one donor group. Gene set enrichment pathways analysis was done using the Broad Institute's GSEA software and MSigDB Hallmark or C7 immunological signatures databases. The latter included datasets: GSE28726 24 , GSE1000001_1577_200_UP 25 , GSE9650 26 and GSE32025 28 . All heat maps are in log 2 scale. The gene expression matrix counts were adjusted for donor effect with Combat (sva package) only for heat maps and clustering. Statistics. Mice were age and gender matched. Among the mice with matched ages and genders, they were randomized and distributed equally into experimental groups. Power analysis was used to estimate the sample size in some experiments, as described in the Reporting Summary. The investigators were not blinded to allocation during experiments and outcome assessment. One-way ANOVA with Sidak's multiple comparisons test was used to determine significant differences among multiple groups with unpaired biological replicates. The two-tailed unpaired Student's t-test was used to determine significant differences between two groups with unpaired biological replicates. The two-tailed paired Student's t-test was used to calculate P values of each pair of independent experiments. The log-rank test was used to determine the significant difference of diabetes incidence. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability. The RNA-seq data have been deposited in the Gene Expression Omnibus under accession number GSE114824. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD009919. 
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Extended Data Fig. 9 | 8F10 T cells exhibit an effector phenotype, but no anergy or exhaustion phenotype, at the transcription level during peripheral antigen recognition. a, Heat maps showing all the enriched genes of the three immunological pathways illustrated in Fig. 4d . b, GSEA enrichment plots performed on differentially expressed genes in 8F10 T cells from the NOD-iLN versus B16A-iLN condition using datasets characterizing CD4 T cell anergy and CD8 T cell tolerance. 
Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
For two-photon analysis, previous studies have shown that the mean track velocity ranges between 7 and 12 micrometers/min with a standard deviation of approximately 4. To have a power of 0.95 and an alpha 0.05, we require a minimal of ~50-60 samples. All of our calculations were derived from a minimal of 60 counted tracks. For competitive ELISA analysis, we have determined that the optical density measurement ranged from a min of 0.3 to 0.6 with a standard deviation of 0.05. To have a power of 0.95 and an alpha of 0.05, we require a minimal of 3 biological replicates, and in all the experiments we included 6 samples. For RNAseq, based on our previous studies we expected an average gene expression level standard deviation of 1-1.5. To have a power of 0.95 and an alpha of 0.05, we required 4 biological replicates per group. For diabetes incidence, with an equal number of animals monitored per group and a relative hazard ratio of 0.5, a minimal of 4 mice per group were required. We included 6 mice per group.
Data exclusions We did not exclude any data from our studies.
Replication
For two-photon analysis, we analyzed 60-200 individual T cells from 2-4 mice per experiment, and the statistical analysis was based 2-4 independent experiments. For ELISA, the statistical analysis was based on 6 independent experiments containing 4-8 mice per experiment. For mass spectrometry, we analyzed two independent experiments with 16-24 mice per experiment. For RANseq, we included 4 biological sample pairs and each pair was from a total of 8-10 mice. For diabetes incidence, we monitored 6 mice per group from 3 independent experiments.
Randomization Mice were age and gender matched. Among the mice with matched ages and genders, they were randomized and distributed equally into experimental groups.
Blinding
All the measurements were performed by instruments or computing devices and therefore blinding is not necessary.
Reporting for specific materials, systems and methods (KJ16-133.18), anti-CD44 (IM7), anti-CD62L (MEL-14), anti-CD25 (PC61.5) and anti-TNFα (MP6-XT22). Unconjugated or Alexa Fluor 647-labelled Rabbit anti-insulin MoAb (C27C9) was purchased from Cell Signaling Technology. Unconjugated mouse antiinsulin MoAb (E11D7) was purchased from Millipore. Alexa Fluor 594 F(ab)2 donkey anti-mouse IgG and HRP-conjugated goat anti-mouse IgG (Fcγ portion specific) were purchased from Jackson ImmunoResearch. All the commercial antibodies were validated by the vendor. The 6F3.B8 antibody recognizing mouse insulin B-chain was generated in the laboratory. The reactivity was confirmed using ELISA.
Validation
All the commercial antibodies were validated by the vendor. The 6F3.B8 antibody recognizing mouse insulin B-chain was generated in the laboratory. The reactivity was confirmed using ELISA.
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s)
The T cell hybridomas used in this study were generated in the laboratory.
Authentication
The reactivity of the T cell hybridomas to their specific antigens was tested using by their ability to produce interleukin-2 when stimulated by corresponding antigens presented by antigen presentation cells.
Mycoplasma contamination
All the cell lines were confirmed mycoplasma free. 
Commonly misidentified lines

Wild animals
The study did not involve wild animals
Field-collected samples
The study did not involve field-collected samples
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation
Single cell suspensions were prepared and incubated with FcR blocking media containing 2.4G2 antibody for 30 min on ice. The cells were then stained for surface markers with corresponding fluorescent antibodies on ice for 25 min.
Instrument
The flow cytometry samples were collected using a FACSCanto II (BD Biosciences). T cell sorting was performed using FACSAria II (BD Biosciences).
Software
Data were collected using FACS DIVA (BD Biosciences) and were analyzed using FlowJo software (Tree Star Software).
Cell population abundance The post sort was performed to confirm a purity above 99%.
Gating strategy
The starting cell population is gated on appropriate FSC/SSC with the default setting of the FACSDiva software. The singlet gate, based on FSH/SSW is applied in all the analyses to exclude doublets. The positive and negative boundaries were determined using isotype control staining or biological control samples. An example of gating strategy is shown in Extended data Figure 8a .
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
